Cantor Fitzgerald assumed coverage of Bright Minds (DRUG) with an Overweight rating and no price target Bright Minds’ lead asset, BMB-101, is a highly selective 5-HT2C receptor agonist in developmental and epileptic encephalopathies and absence epilepsy, the analyst tells investors in a research note. BMB-101 may deliver improved efficacy, safety, and durability vs. competitors, the firm says.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences to Present at 2025 Jefferies Global Healthcare Conference
- Bright Minds Biosciences’ BMB-101: A Promising Breakthrough in Treatment-Resistant Epilepsy
- Bright Minds Biosciences: Buy Rating Issued on Promising Potential of BMB-101 for Absence Seizures
- Bright Minds Biosciences Hosts Virtual R&D Day on Absence Epilepsy
- Bright Minds announces speakers for Absence epilepsy R&D Day